| Literature DB >> 26252010 |
Robert B Lochhead1, James F Zachary2, Luciana Dalla Rosa3, Ying Ma1, John H Weis1, Ryan M O'Connell1, Janis J Weis1.
Abstract
MicroRNA-155 has been shown to play a role in immune activation and inflammation, and is suppressed by IL-10, an important anti-inflammatory cytokine. The established involvement of IL-10 in the murine model of Borrelia burgdorferi-induced Lyme arthritis and carditis allowed us to assess the interplay between IL-10 and miR-155 in vivo. As reported previously, Mir155 was highly upregulated in joints from infected severely arthritic B6 Il10-/- mice, but not in mildly arthritic B6 mice. In infected hearts, Mir155 was upregulated in both strains, suggesting a role of miR-155 in Lyme carditis. Using B. burgdorferi-infected B6, Mir155-/-, Il10-/-, and Mir155-/- Il10-/- double-knockout (DKO) mice, we found that anti-inflammatory IL-10 and pro-inflammatory miR-155 have opposite and somewhat compensatory effects on myeloid cell activity, cytokine production, and antibody response. Both IL-10 and miR-155 were required for suppression of Lyme carditis. Infected Mir155-/- mice developed moderate/severe carditis, had higher B. burgdorferi numbers, and had reduced Th1 cytokine expression in hearts. In contrast, while Il10-/- and DKO mice also developed severe carditis, hearts had reduced bacterial numbers and elevated Th1 and innate cytokine expression. Surprisingly, miR-155 had little effect on Lyme arthritis. These results show that antagonistic interplay between IL-10 and miR-155 is required to balance host defense and immune activation in vivo, and this balance is particularly important for suppression of Lyme carditis. These results also highlight tissue-specific differences in Lyme arthritis and carditis pathogenesis, and reveal the importance of IL-10-mediated regulation of miR-155 in maintaining healthy immunity.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26252010 PMCID: PMC4529177 DOI: 10.1371/journal.pone.0135142
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Expression of Mir155 in hearts, ankle skin, and joints of B6 and Il10-/- mice.
| Strain |
|
|
| |||
|---|---|---|---|---|---|---|
| Control | Infected | Control | Infected | Control | Infected | |
| B6 | 1.8 (±0.02) |
| 0.1 (±0.04) | 0.1 (±0.01) | 0.16 (±0.01) | 0.13 (±0.02) |
| Il10-/- | 2.0 (±0.1) |
| 0.05 (±0.04) |
| 0.13 (±0.03) |
|
Lyme carditis severity in 4 strains.
| Strain | Overall lesion | PMN infiltrate | Mononucl infiltrate | Vasculitis severity | Total score |
|---|---|---|---|---|---|
|
| |||||
| B6 | 1.4 (±0.2) | 0.6 (±0.1) | 0.6 (±0.1) | 0.6 (±0.2) | 3.0 (±0.4) |
| Mir155-/- | 2.0 (±0.3) |
| 1.4 (±0.2) |
|
|
| Il10-/- |
|
|
|
|
|
| DKO |
|
|
|
|
|
|
| |||||
| B6 | 0.6 (±0.2) | 0.6 (±0.2) | 0.9 (±0.1) | 1.1 (±0.2) | 3.9 (±0.3) |
| Mir155-/- |
|
| 1.1 (±0.1) |
|
|
| Il10-/- |
|
|
|
|
|
| DKO |
|
|
|
|
|
Lyme arthritis severity in 4 strains.
| Strain | Ankle swelling | Overall lesion | PMN Infil. | Mono Infil. | Sheath thickness | Reactive/Repar. | Total score |
|---|---|---|---|---|---|---|---|
| B6 | 0.29(±0.06) | 1.7(±0.4) | 1.1(±0.3) | 0.2(±0.1) | 1.4(±0.3) | 1.0(±0.5) | 5.3 (±1.3) |
| Mir155-/- | 0.18(±0.04) | 1.1(±0.3) | 0.4(±0.1) | 0.3(±0.1) | 1.9(±0.2) | 0.3(±0.1) | 3.1 (±0.7) |
| Il10-/- |
| 2.5(±0.3) |
|
|
| 0.8(±0.4) |
|
| DKO |
| 2.7(±0.4) |
|
|
| 2.0(±0.5) |
|
Expression of Th1 and innate cytokines in hearts of infected mice.
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| B6 | 0.2 (±0.04) |
| 1.9 (±0.7) | 1.7 (±0.1) | 3.3 (±0.3) | 2.3 (±0.3) |
| Mir155-/- | 0.08 (±0.04) |
| 1.5 (±0.4) | 1.6 (±0.4) | 1.7 (±0.4) | 2.2 (±0.2) |
| Il10-/- | 0.8 (±0.3) |
| 1.7 (±0.5) |
| 1.4 (±0.1) |
|
| DKO | 0.3 (±0.06) |
| 1.5 (±0.4) |
| 1.6 (±0.4) |
|
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| B6 | 1.3 (±0.3) | 0.4 (±0.1) | 1.8 (±0.4) | 1.1 (±0.1) | 0.6 (±0.3) | 0.8 (±0.1) |
| Mir155-/- | 0.6 (±0.1) | 0.8 (±0.2) | 0.8 (±0.1) | 1.9 (±0.5) | 0.4 (±0.04) | 0.9 (±0.3) |
| Il10-/- | 1.0 (±0.6) |
| 1.0 (±0.3) |
| 0.6 (±0.3) |
|
| DKO | 0.2 (±0.1) |
| 1.9 (±0.3) |
| 0.5 (±0.1) |
|
Expression of cytokines in joints of infected mice.
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| B6 | 0.09 (±0.01) | 0.17 (±0.03) | 0.9 (±0.2) | 1.5 (±0.4) | 0.6 (±0.1) |
|
| Mir155-/- | 0.07 (±0.03) | 0.15 (±0.04) | 0.8 (±0.4) | 0.9 (±0.1) | 0.7 (±0.1) |
|
| Il10-/- | 0.08 (±0.01) |
| 1.0 (±0.2) |
| 0.6 (±0.1) |
|
| DKO | 0.16 (±0.04) |
| 0.9 (±0.3) |
| 1.2 (±0.1) |
|
|
| ||||||
|
|
|
|
| |||
|
|
|
|
|
|
| |
| B6 | 0.8 (±0.3) | 1.0 (±0.2) | 1.0 (±0.1) | 1.0 (±0.2) | 0.2 (±0.03) | 0.2 (±0.04) |
| Mir155-/- | 1.1 (±0.2) | 0.7 (±0.2) | 0.6 (±0.1) | 0.8 (±0.1) | 0.2 (±0.04) | 0.2 (±0.05) |
| Il10-/- | 1.1 (±0.6) |
| 0.6 (±0.2) |
| 0.3 (±0.01) | 0.4 (±0.06) |
| DKO | 0.3 (±0.1) |
| 0.6 (±0.1) |
| 0.2 (±0.02) | 0.3 (±0.06) |